Shelley Boyd

Shelley Boyd

Company: Translatum Medicus inc, Tracery Ophthalmics inc

Job title: President & CEO


In vivo visualization of Macrophages in Ocular Oncology 2:30 pm

Melanocytic tumours in the eye can be benign or highly malignant, with many classified as “indeterminate” presenting a diagnostic challenge to clinicians Tumour associated macrophages (TAMs) are reported in histopathological specimens of choroidal melanoma and are absent in nevi We are focused on developing novel image acquisition methods, image based biomarkers, and advanced computing for…Read more

day: Discovery & Pre-Clinical Development – Day 2 pm

Macrophage Modulation for “dry” Age Related Macular Degeneration 3:00 pm

AMD is a leading cause of irreversible blindness, with no approved treatments for the late “dry” form of disease characterized by Geographic Atrophy (GA) We are focused on the transcriptional regulation of macrophage polarization Our lead candidate dose-dependently reduces the onset and expansion of GA-like atrophy, reducing M1 activity and downstream effectors such as complement…Read more

day: Focus Day

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.